Updated:
Ocuphire Pharma
Ocuphire Pharma is based in Farmington Hills; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
Groundbreaking gene therapy built by and for patients with rare inherited retinal diseases (IRD)
General information
Location
Region
North America
Country
United States
City
Farmington Hills
Corporate office
Farmington Hills, MI, United States
Principals
Jean Bennett
Scientific Advisor
Sector focus
Frequently asked questions
What disease areas does Ocuphire Pharma target?
Ocuphire Pharma focuses on inherited retinal diseases (IRDs) and other retinal and refractive disorders. Specific mutations under investigation include those causing bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa (RP), per the firm's website.
Who are the key scientific leaders behind Ocuphire Pharma?
Dr. Jean Bennett serves as Scientific Advisor. Dr. Bennett is a recognized leader in gene therapy for blinding diseases, and her involvement signals a research-intensive approach to the company's IRD pipeline.
Is Ocuphire Pharma a publicly traded company?
The firm's public listing status is not disclosed on its website. As a clinical-stage biopharmaceutical with no disclosed funding rounds or ticker symbol in available sources, its capital structure remains unverified.
How does Ocuphire Pharma approach gene therapy for retinal diseases?
The company describes building an engine to develop treatments for mutations in genes that cause vision loss. Its stated goal is to preserve vision by targeting the underlying genetic drivers of IRDs.
Where is Ocuphire Pharma located?
The company is headquartered in Farmington Hills, Michigan, United States. No additional office locations are publicly listed.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: